Today: 21 March 2026
Browse Category

NASDAQ:CNTA 11 December 2025

Centessa Pharmaceuticals (CNTA) Stock on December 11, 2025: CEO Shake‑Up, Analyst Upgrades and 2026 Orexin Catalysts

Centessa Pharmaceuticals (CNTA) Stock on December 11, 2025: CEO Shake‑Up, Analyst Upgrades and 2026 Orexin Catalysts

Centessa Pharmaceuticals announced Mario Alberto Accardi will become CEO on January 1, 2026, as the company’s orexin drug program nears pivotal studies. Shares fell 8.4% to about $27 after the news. Current CEO Saurabh Saha will move to an advisory role. The company’s lead candidate, ORX750, is set for registrational trials in early 2026.

Stock Market Today

  • 3 Reasons to Avoid Adobe Stock and a Better Pick Instead
    March 20, 2026, 7:21 PM EDT. Adobe's stock has fallen 32.4% since September 2025, dropping to $246.27 amid concerns over slowing growth. The company's annual recurring revenue (ARR) grew 13% last year, lagging the software sector. Analysts project revenue growth to slow to 8.5% over the next 12 months, signaling potential demand challenges. Adobe's operating margin, a key profitability metric including stock-based compensation (SBC) costs, has remained flat around 36.6%, raising concerns about expense management. Trading at 3.8 times forward price-to-sales, Adobe's valuation is fair but offers limited upside. Instead, investors may prefer more resilient names like companies owning brands such as Taco Bell, seen as stronger long-term plays in uncertain markets.
Go toTop